CBU
AZN icon

CIBC Bancorp USA’s AstraZeneca AZN Stock Holding History

CIBC Bancorp USA’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$681M Sell
3,772,997
-822,895
-18% -$155M 0.83% 20
2026
Q1 		$870M Buy
+4,595,892
New +$886M 1.17% 11
2025
Q3 		$1.65M Buy
+10,754
New +$1.63M 0.01% 616

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

CIBC Bancorp USA's AZN Position: Q2 2026 in Review

CIBC Bancorp USA reduced its AstraZeneca (AZN) stake by 18% in Q2 2026, selling an estimated $155M and leaving 3,772,997 shares worth $681M. The position accounts for 0.83% of the portfolio, ranked #20.

CIBC Bancorp USA first reported a position in AZN in Q3 2025 and has held it in 3 quarters since. The position peaked at $870M in Q1 2026. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • CIBC Bancorp USA held 3,772,997 shares of AstraZeneca worth $681M as of Q2 2026.
  • CIBC Bancorp USA sold 822,895 AstraZeneca shares in Q2 2026, an estimated $155M.
  • AstraZeneca made up 0.83% of CIBC Bancorp USA's portfolio in Q2 2026, its #20 holding.
  • CIBC Bancorp USA first reported a position in AstraZeneca in Q3 2025 and has held it in 3 quarters since.
  • CIBC Bancorp USA's AstraZeneca position peaked at $870M in Q1 2026.
  • 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on CIBC Bancorp USA's 13F filing for Q2 2026, filed 13 Aug 2026.